Overview

Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma

Status:
Recruiting

Trial end date:
2023-08-01

Target enrollment:

Participant gender:

Summary

This phase II trial studies the effects of iberdomide when given alone or in combination with dexamethasone in treating intermediate or high-risk smoldering multiple myeloma patients. Immunotherapy with iberdomide may induce changes in body's immune system and may interfere with the ability of cancer cells to grow and spread. Dexamethasone is a synthetic steroid (similar to steroid hormones produced naturally in the adrenal gland), and is used with other drugs in the treatment of some types of cancer. Giving iberdomide with dexamethasone my improve time to progression to symptomatic myeloma with improved tolerability.

Phase:

Phase 2

Details

Lead Sponsor:

Emory University

Collaborator:

Bristol-Myers Squibb

Treatments:

BB 1101
Dexamethasone
Dexamethasone acetate
Ichthammol